Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the Sugar Business, sales of products for commercial use increased due to the Osaka-Kansai Expo and growing tourism and inbound demand. The business also worked to procure and sell products at appropriate prices, resulting in higher revenue and profit. In the Bio Business, sales of certain consumer and commercial products remained sluggish, resulting in lower revenue and profit.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥32,982 million (YoY +1.4%) |
| Operating profit | ¥3,047 million (YoY +5.8%) |
| Ordinary income | ¥3,339 million (YoY +9.4%) |
| Profit attributable to owners of the parent | ¥2,765 million (YoY +29.4%) |
| Net income per share | ¥100.58 |
| Operating Margin | 9.2 % |
| Equity ratio | End of the current fiscal period 64.8 / End of previous period 56.5 |
| Total assets | ¥31,813 million |
| Net assets | ¥20,603 million |
| Cash flows from operating activities | ¥2,658 million |
| Cash flows from investing activities | ¥-1,132 million |
| Cash flows from financing activities | ¥-1,928 million |
| Cash and cash equivalents at end of period | ¥2,892 million |
| Full-year earnings forecast | Net Sales ¥32,100 million (YoY -2.7%) / Operating profit ¥2,400 million (YoY -21.3%) / Ordinary income ¥2,600 million (YoY -22.1%) / Profit attributable to owners of the parent ¥1,800 million (YoY -34.9%) |
| Annual Dividend Forecast | ¥20 → ¥16（-20.0%） |
| Payout ratio | 19.9 |
| Segment revenue | Sugar business ¥31,368 million (YoY +1.6%), Bio Business ¥1,603 million (YoY -1.3%), Other ¥139 million (YoY +2.8%) |
| Segment profit | Sugar business ¥4,193 million (YoY +8.7%), Bio Business ¥282 million (YoY -10.7%), Other ¥77 million (YoY -0.2%) |
| Depreciation and amortization | ¥602 million |
| Impairment loss | ¥3 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥605 million / Extraordinary loss Impairment Losses ¥3 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies (company name: —) / Excluded 0 companies (company name: —) |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 35,000,000 shares |
| Treasury Shares at Period-End | 7,480,346 shares |
| Factors Behind Changes in Business Performance | In the Sugar Business, sales of products for commercial use increased due to the Osaka-Kansai Expo and growing tourism and inbound demand. The business also worked to procure and sell products at appropriate prices, resulting in higher revenue and profit. In the Bio Business, sales of certain consumer and commercial products remained sluggish, resulting in lower revenue and profit. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.During the fiscal year, sales of sugar products for commercial use increased amid the Osaka-Kansai Expo and growing tourism and inbound demand. The Sugar Business also worked to procure and sell products at appropriate prices, resulting in higher revenue and profit. The Bio Business reported lower revenue and profit due to sluggish sales of certain consumer and commercial products. For the next fiscal year, the Company cited the unstable foreign exchange market, uncertainty in overseas economies, and trends in raw material and energy prices, among other factors.